CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice
News

Novartis and Ratio Enter Radiotherapeutics Partnership Worth $745m

Novartis and Ratio Therapeutics have entered into a worldwide licence and collaboration agreement worth $745m to advance a somatostatin receptor 2 (SSTR2)-targeting ...
Continue Reading →
Volume 15 Issue 3

A New Age of Pharmaceutical Innovation

IPI Speaks with Dr Patrick Larcier, Senior Director, Strategy Product Development Solutions, EU & US, of PharmaLex, on Next-generation Small Molecules Q: Can ...
Continue Reading →
Volume 15 Issue 2

The Future of AI in Biotechnology

On the Precipice of the New Technological Revolution The artificial intelligence revolution kicked into high gear seemingly overnight. Generative AI platforms lik...
Continue Reading →
Volume 15 Issue 1

Into the Future with Next-generation Small Molecules

Heightened interest in small molecules is likely to continue in 2023 and beyond as several biotech companies look beyond biologics to bring medicines to patients in ...
Continue Reading →
News

BIOCAD launches the new manufacturing site in North Africa

Russian biotechnology company BIOCAD and Moroccan pharmaceutical company Sothema Labs announced the launch of medicines derived using the technology provided by the ...
Continue Reading →
News

Locus Biosciences raises $19 million series A for CRISPR-Cas3 Antimicrobials

Locus Biosciences has closed $19 million in Series A funding led by venture capital firm ARTIS Ventures with additional financing from notable institutional investor...
Continue Reading →
News

Poor aggregation will see ADC targets fail or face long delays

ADC Biotechnology (ADC Bio)‘s leading experts warn that best in class ADCs are being overlooked due to critical aggregation control problems. CDMOs are unable to dev...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026